Article Text

Download PDFPDF
CRISPR immunity: a case study for justified somatic genetic modification?
  1. Eli Y Adashi1,
  2. Ivan Glenn Cohen2
  1. 1 Medical Science, Brown University, Providence, Rhode Island, USA
  2. 2 Harvard Law School, Cambridge, Massachusetts, USA
  1. Correspondence to Professor Eli Y Adashi, Medical Science, Brown University, Providence, RI 02906, USA; eli_adashi{at}brown.edu

Abstract

The current SARS-CoV-2 pandemic has killed thousands across the world. SARS-CoV-2 is the latest but surely not the last such global pandemic we will face. The biomedical response to such pandemics includes treatment, vaccination, and so on. In this paper, though, we argue that it is time to consider an additional strategy: the somatic (non-heritable) enhancement of human immunity. We argue for this approach and consider bioethics objections we believe can be overcome.

  • clinical ethics
  • enhancement
  • ethics
  • genetic engineering

Data availability statement

There are no data in this work.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

There are no data in this work.

View Full Text

Footnotes

  • Twitter @cohenProf

  • Contributors Both authors contributed equally to the writing of the submitted manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Other content recommended for you